30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

3Q14 Revenue: Stryker

$2,389MM, +11% (U.S. $1,628MM, +12%; ex-U.S. $761MM, +9%: China >20%)

Reconstructive $1,016MM, +9% (U.S. +12%, ex-U.S. +4%)

  • Hips $316MM, +4% (U.S. +8%, ex-U.S. -1%)
  • Knees $335MM, +6% (U.S. +7%, ex-U.S. +5%)
  • Trauma/Extremities $309MM, +12% (U.S. +15%, ex-U.S. +8%)

MedSurg Equipment $936MM, +17% (U.S. +15%, ex-U.S. +20%)

  • Endoscopy $345MM, +19% (U.S. +15%, ex-U.S. +30%)

Neurotechnology/Spine $437MM, +7% (U.S. +7%, ex-U.S. +8%)

  • Spine $186MM, +2% (U.S. +1%, ex-U.S. +6%)

MedSurg includes instruments and medical equipment.


  • Pricing update: overall pricing -2.3%: U.S. hip/knee pure price stable vs. 2Q, declines in spine and trauma
  • MAKO sales “pacing below our target” but pipeline and clinical progress encouraging; Berchtold, Patient Safety Technologies and Trauson on track; Pivot Medical and Small Bone Innovations (SBi) tracking ahead
  • MAKO update: Sold 8 robotic systems in 3Q, completed enrollment in Triathlon total knee trial, developed flexible finance offering
  • SBI update: >100 Stryker reps trained on STAR ankle and other products; will train >200 on STAR and >400 on upper extremity products; to date, >28,000 STAR ankles implanted globally, >100 clinical studies
  • U.S. foot/ankle +>30% (excluding SBi)
  • Most growth in extremities attributed to expanding market, calling on new surgeons who weren’t putting in implants, previously, as well as new products
  • Upgrading spine portfolio to include more MIS products